Nov 14, 2000 by Jeff FischerAdvantages of DripsDid you know you need very little money to start Drip investing? Jeff Fischer details all the advantages.
Nov 8, 2000 by Jeff FischerNew Tracking MethodFrom now on, the Drip Portfolio will track its results against the S&P 500. Find out why.
Nov 7, 2000 by Jeff FischerThe Hunt for High GrowthJeff Fischer cuts three companies from the list of possible high-growth investments.
Nov 6, 2000 by Jeff FischerAmazon Wants To Be eBayYou can buy a new book from Amazon.com. Or an old one. What's happened to the brand?
Oct 30, 2000 by Jeff FischerAmgen Must Renew ItselfJeff Fischer wants to see Amgen back up its aging blockbuster drugs with new ones.
Oct 26, 2000 by Jeff FischerRetire at Any AgeRetirement means financial independence. So if you plan ahead, you could retire at any age.
Oct 24, 2000 by Jeff FischerMy Favorite Stock, eBayJeff Fischer reviews eBay's earnings and test-drives eBay subsidiary Half.com.
Oct 24, 2000 by Jeff FischerIntel, AMD Could CoexistTwo Fools explain why they think both Intel and AMD could succeed in the long run.
Oct 18, 2000 by Jeff FischerBuying More IntelWe're buying more Intel because its year-over-year earnings growth is still strong, although its price has dropped.
Oct 17, 2000 by Jeff FischerBiotech's Fatal AttractionIf you're flirting with high-flying biotech stocks, be prepared for the possible backlash. Remember drkoop.com?
Oct 17, 2000 by Jeff FischerJ&J for What Ails YaJohnson & Johnson reports third-quarter earnings growth and tops expectations as it continues to innovate in healthcare. Jeff Fischer reports.
Oct 17, 2000 by Jeff FischerBiotech's Fatal AttractionIf you're flirting with high-flying biotech stocks, be prepared for the possible backlash. Remember drkoop.com?
Oct 17, 2000 by Jeff FischerBiotech's Fatal AttractionIf you're flirting with high-flying biotech stocks, be prepared for the possible backlash. Remember drkoop.com?
Oct 12, 2000 by Jeff FischerIntel and J&J PreviewsThe chipmaker and the drugmaker report earnings on Tuesday. What should investors expect?
Oct 11, 2000 by Jeff FischerProfits Pop at PepsiEach of Pepsi's four divisions grew operating profits by double-digits last quarter. Yowza!
Oct 4, 2000 by Jeff FischerHuman Genome Sciences' PipelineThe company has six drugs in clinical trials. But investors should be ready to hold this stock for at least five years.
Sep 28, 2000 by Jeff FischerHigh-Growth Semi-FinalistsWe're narrowing the field in our search for high-growth companies. And we need your help.
Sep 26, 2000 by Jeff FischerAfter Intel's FallWe're buying more Intel this week, even though it took a hit last week. But plenty of Fools would say we're wrong.
Sep 26, 2000 by Jeff FischerPriceline as Rule BreakerIt's the top dog in its industry and has a strong consumer brand. But the management team is hard to assess.
Sep 21, 2000 by Jeff FischerMaking the High-Growth CutWe narrow the field in our search for a high-growth investment with our first round of cuts.
